University of Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).
University of Chicago: 796 sponsored US clinical trials, 158 recruiting.
University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.
Top-decile sponsor footprint
University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
796 total, page 13 of 16
Safety Study of Abatacept to Treat Refractory Sarcoidosis
NCT00739960
Thermal Analgesia in Newborns
NCT00740298
Glucose Metabolism and Sleep in People With Family History of Type 2 Diabetes.
NCT00720889
Pharmacokinetics of Implanon in Obese Women
NCT00724438
Acceptability of the NuvaRing Among Students
NCT00635570
Sleep Loss and Glucose Metabolism in People With Family History of Type 2 Diabetes.
NCT00721019
Fitness and Sleep in People With Family History of Type 2 Diabetes.
NCT00721084
Sleep Loss and Energy Metabolism in People With Family History of Type 2 Diabetes.
NCT00724087
Inhaled Nitric Oxide and Neuroprotection in Premature Infants
NCT00515281
Rapamycin Plus Bevacizumab in Advanced Cancers
NCT00667485
Treatment of Insomnia and Glucose Metabolism
NCT00724282
REACH-OUT: Chicago Children's Diabetes Prevention Program
NCT00723853
Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?
NCT00618332
Intranasal CO2 for Allergic Rhinitis
NCT00618410
Statins for the Early Treatment of Sepsis
NCT00528580
Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome
NCT00603044
Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
NCT00607477
Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea
NCT00696111
Metabolic Study of Sleep Apnea in Men and Women
NCT00706511
Clofarabine Bone Marrow Cytoreduction
NCT00724009
Sleep Disturbances as a Non-traditional Risk Factor in CKD-Actigraphy
NCT00817674
Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients
NCT00739843
Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer
NCT00548626
Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers
NCT00583063
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
NCT00529802
Behaviors of Children Ages 15 Months to Five Years Around Microwave Ovens
NCT01112124
Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation
NCT00528853
Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation
NCT00513019
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
NCT00523432
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
NCT00517361
Speech and Language Therapy After Stroke
NCT00713050
Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial
NCT00653159
Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer
NCT00515112
Intranasal Steroids and Oxymetazoline in Allergic Rhinitis
NCT00584987
Predictors of the Metabolic Effect of Sleep Loss
NCT00965783
GI Reflux in Lung Transplant and Its Relationship to Chronic Rejection
NCT00455078
Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion
NCT00635362
Vaccination Plus Ontak in Patients With Metastatic Melanoma
NCT00515528
Intranasal Steroids and the Nasal Ocular Response
NCT00473915
Voriconazole as Prophylactic Therapy in Lung Transplant Recipients
NCT00455364
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
NCT00452218
Sleep Disordered Breathing and Diabetes
NCT00901472
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
NCT00590681
Primary Care Based Depression Prevention for Adolescents/Young Adults/Young Adults and Young Adults
NCT00145912
Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk
NCT00915707
Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.
NCT00409526
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
NCT00449280
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
NCT00943800
Rapamycin With Grapefruit Juice for Advanced Malignancies
NCT00375245
A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs
NCT00831129
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 156 |
| Phase 3 | 14 |
| Phase 4 | 53 |
Therapeutic Areas
What is open in the University of Chicago pipeline
158 recruiting of 796 indexed (20% open); 451 completed (57%).
Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Chicago: open-pipeline peers nationwide
Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 796 trials (± recruiting share)
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
- University of Utah · 818 trials · 17% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this University of Chicago page
796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.
- 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.